eculizumab biosimilar
Marketedupdated 2mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 20 investigational indications.
all catalysts(7)
approval · 7
May 28, 2024
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Oct 23, 2024
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Jan 30, 2025
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Apr 18, 2025
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Sep 17, 2025
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Nov 24, 2025
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
Mar 26, 2026
approval
BKEMV (ECULIZUMAB-AEEB) — FDA approval
eculizumab biosimilar
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that